<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FA473957-A6EE-4164-867C-CEF3FACBFF3C"><gtr:id>FA473957-A6EE-4164-867C-CEF3FACBFF3C</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Malim</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001081"><gtr:id>6D87842B-D8B3-41F8-8A65-238EEE1EB2F3</gtr:id><gtr:title>Exploiting species-specific defects in virion assembly to identify cellular co-factors for HIV-1 replication</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001081</gtr:grantReference><gtr:abstractText>As adult, paediatric and adolescent HIV-1 infections continue to spread worldwide, the development of further anti-retroviral treatments remains of the utmost importance; for instance, there is no effective HIV-1 vaccine, and current front-line therapies targeting the viral reverse transcriptase and protease enzymes are compromised by compliance, toxicity and viral resistance concerns. Pursuing other HIV-1 (or human) proteins as anti-viral targets is therefore critical, but their rational selection requires a fundamental understanding of underlying biological principles. Work from many laboratories has contributed to the current understanding of virus assembly ? the process where nascent infectious particles are formed in infected cells in readiness for release and subsequent rounds of viral spread. One experimental approach for addressing key steps in the HIV-1 life cycle is to study them in contexts where they are non-functional, e.g., in cells derived from non-human species. Indeed, it has been clearly established that HIV-1 assembly is markedly inefficient in mouse cells. Here, we will exploit this species-specific defect together with complementing genetic and proteomic methodologies to identify novel cellular co-factors important for the assembly of infectious HIV-1 particles. The underlying basis for function will be addressed using contemporary biochemical, molecular genetic and imaging experiments, with the expectation, for instance, that we will gain novel insight into how the movement of RNA molecules within cells can impact protein function, and how these processes may be impeded to achieve viral inhibition. Lastly, the co-factors that are identified will be applied to cultured mouse cell systems that aim to recapitulate spreading HIV-1 infection, a feat not yet accomplished in the field: achieving this is particularly important as it would pave the way for establishing a living mouse model for HIV-1 infection, which would have tremendous utility for, inter alia, studies of HIV/AIDS pathogenesis, vaccines and therapeutics. The Public Relations Dept of KCL is primarily responsible for communicating our work to the public; and a ?Directory of Experts? is maintained that enables members of the public to identify academics willing to discuss specialist areas. For instance, MHM has given numerous interviews to the press, has appeared on television and has advised the BBC on the content of AIDS-related programming. He is also a Section Editor of a public access journal, PLoS Pathogens, has given overview seminars on the value of scientific research at Community Liaison Meetings (e.g., Cafe Scientifique), and helps organise Conferences attended by non-scientific members of the HIV/AIDS community.</gtr:abstractText><gtr:technicalSummary>The assembly of infectious HIV-1 particles requires the co-ordinated activities of viral gene products, particularly Gag and RNA, and cellular co-factors and pathways. Unlike human cells, rodent cells are notably deficient in supporting effective HIV-1 core assembly. By understanding the principles for such species-specific replication barriers, investigators have been able to learn a great deal about the interactions of HIV-1 with infected host cells. Indeed, previous work has established that the murine cell assembly deficiency is rescued by human co-factors provided in trans, by manipulating the membrane binding capabilities of the viral Gag protein, or by changing the nuclear export pathway used by viral RNA. Here, we outline an inter-disciplinary and collaborative project that aims to identify human co-factors important for HIV-1 assembly, and to define the mechanistic basis for their activities. First, we will conduct gain-of-function ?genetic? screens in murine cells to identify human cDNAs that can promote HIV-1 assembly; in parallel, and in collaboration with the Frankel and Sundquist groups, we will perform comparative proteomic screens for factors that interact with HIV-1 Gag, Rev or RNA in a manner that correlates with effective assembly. Second, subsequent cell biological, molecular genetic and biochemical assays in both murine- and human-based assay systems will address the molecular mechanism(s) that underlie the rescue of assembly, focusing on question such as interactions with viral and cellular RNAs and proteins, sub-cellular localisation, intra-cellular trafficking and viral infectivity. Importantly, our preliminary data validate the utility of the genetic strategy in that the human orthologues of the SR proteins, SRp40 and SRp55, as well as the nuclear export receptor, CRM1, can each stimulate assembly in murine cells; the mechanisms of action differ, however, in that SR proteins increase Gag expression whereas CRM1 has a dramatic effect on the efficiency of assembly itself. Finally, validated assembly co-factors will be co-expressed with established human co-factors (e.g., CD4, CYCT1) in attempts to create murine cells capable of supporting spreading HIV-1 replication. Though beyond the scope of this work, developing a living mouse model for HIV/AIDS infection has the potential to be highly instructive for work on pathogenesis, immune responses, transmission, vaccines, etc. In sum, we aim to identify novel interactions between HIV-1 and infected host cells that regulate virus assembly, with the goal of better understanding general principles of virus replication and human cell biology, as well as defining rational targets for future therapeutic exploitation.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>689329</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1822984</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Senior Investigator Award</gtr:department><gtr:description>Wellcome Trust Senior Investigator</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>106223/Z/14/Z</gtr:fundingRef><gtr:id>0A514522-E38E-4238-971A-2788E49AC2B4</gtr:id><gtr:outcomeId>56b88bcdbaedd4.39108455</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Expression vectors for HIV proteins, cellular proteins, as well as tagged and mutated derivatives thereof have been constructed in a variety of plasmid- and retrovirus-based vectors</gtr:description><gtr:id>687807E3-A5E5-431F-93D0-1B8CCA6EBB57</gtr:id><gtr:impact>The work on APOBEC proteins as natural inhibitors of HIV/SIV infection has founded new fields of research, not only on these proteins but, more broadly, on cell-based mechanisms of virus resistance (TRIM, tetherin, etc). Much of this work relies on reagents such as those developed in this lab.</gtr:impact><gtr:outcomeId>859E5BC90B7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression vectors for HIV- or cell-encoded proteins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C5E56C59-CA92-4012-ABDA-CB7A8F3D7486</gtr:id><gtr:title>Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>cJB7RK6bzJ1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D09AADB-0657-4CD6-B36E-7A6D2359FCF9</gtr:id><gtr:title>Nuclear import of SAMHD1 is mediated by a classical karyopherin a/?1 dependent pathway and confers sensitivity to VpxMAC induced ubiquitination and proteasomal degradation.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>5448f3683f8cd4.51945801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>098331B4-C45F-4F56-8A85-AA840F1ABA3A</gtr:id><gtr:title>Evidence for IFNa-induced, SAMHD1-independent inhibitors of early HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14565_25_23442224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AF0A29E-3D8A-4697-A438-3FF2F515ECF0</gtr:id><gtr:title>HIV Restriction Factors and Mechanisms of Evasion.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_14565_25_22553496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>269637CB-5588-409F-8634-45813E234229</gtr:id><gtr:title>HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c289ea9f855e7d4ef862dedff62b35b1"><gtr:id>c289ea9f855e7d4ef862dedff62b35b1</gtr:id><gtr:otherNames>Phalora PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_22915799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>801FA84A-CA7D-4B55-8FBB-F4FFF3107F60</gtr:id><gtr:title>Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b6bba42ade1380857ec0ebbc773da57"><gtr:id>4b6bba42ade1380857ec0ebbc773da57</gtr:id><gtr:otherNames>Lu Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5448f30347cfa2.96562727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5626A12A-11EF-4C83-A815-4038E4908E55</gtr:id><gtr:title>New insights into an X-traordinary viral protein.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>5448f38c7469a6.43823278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B64155A4-5D21-408D-A75E-C2436F870B62</gtr:id><gtr:title>Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01aac83b8549060d77dffdc6ae1fd282"><gtr:id>01aac83b8549060d77dffdc6ae1fd282</gtr:id><gtr:otherNames>Arjan-Odedra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14565_25_22727223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47444CAF-553D-41A1-AD82-0D867E7EF331</gtr:id><gtr:title>Cooperativity among Rev-associated nuclear export signals regulates HIV-1 gene expression and is a determinant of virus species tropism.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50144aa725fb847b17f9a2c310811208"><gtr:id>50144aa725fb847b17f9a2c310811208</gtr:id><gtr:otherNames>Aligeti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5448f3f467dde6.92876702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3EAB656-1577-4FA8-82E4-AD906798F2D8</gtr:id><gtr:title>Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_14565_25_24048477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B33F5EE0-5DED-409A-A577-D2BAB29606B7</gtr:id><gtr:title>Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5448f3b5630780.23820469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>410796A0-5264-4C4B-9266-A4EC2A07BBEB</gtr:id><gtr:title>A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a0ff0ef24bc64a468e4f87b0b43c0b"><gtr:id>74a0ff0ef24bc64a468e4f87b0b43c0b</gtr:id><gtr:otherNames>Goujon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56b889c398a345.18694134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B451B74-9418-4AF6-853A-382094F88655</gtr:id><gtr:title>Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/292b41fa56f474420b9e8bde21def9a9"><gtr:id>292b41fa56f474420b9e8bde21def9a9</gtr:id><gtr:otherNames>Mlcochova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5675e1961a9f1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3849112-DE82-4DFB-98B7-C98D689BE443</gtr:id><gtr:title>AIDS/HIV. HIV interplay with SAMHD1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b80e4206e65c27027c5eb4c5816ed08"><gtr:id>2b80e4206e65c27027c5eb4c5816ed08</gtr:id><gtr:otherNames>Schaller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14565_25_22422971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>955C273B-B4CD-45EC-8B72-D05918D7EFC4</gtr:id><gtr:title>HIV-1 and interferons: who's interfering with whom?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ef4bc924b19c7e189b6f654810964e"><gtr:id>68ef4bc924b19c7e189b6f654810964e</gtr:id><gtr:otherNames>Doyle T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>56b88a0ca42b54.41736026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF13500-82AD-41DE-905B-FC9932D34852</gtr:id><gtr:title>Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a84d7fc0c78b0b04b5b583554dc7ff07"><gtr:id>a84d7fc0c78b0b04b5b583554dc7ff07</gtr:id><gtr:otherNames>Sherer NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>EQvYXK9uqVQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BB138F2-1B7D-47B2-B254-B73917062866</gtr:id><gtr:title>Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f3a76b86c1f9a984be4d45a8faa279a"><gtr:id>3f3a76b86c1f9a984be4d45a8faa279a</gtr:id><gtr:otherNames>Apolonia L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>doi_55faa2aa20c8fb2d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6863F6F0-52A7-44B0-8307-179C3068FBC4</gtr:id><gtr:title>Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0081983a84256e14922a086b8b9919"><gtr:id>2d0081983a84256e14922a086b8b9919</gtr:id><gtr:otherNames>Gillick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14565_25_23152537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D928B12A-2A63-49A0-A89D-E2DB8B779573</gtr:id><gtr:title>HIV: Ringside views.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cdaef89f33d6b94fb92520b444ffcf"><gtr:id>08cdaef89f33d6b94fb92520b444ffcf</gtr:id><gtr:otherNames>Malim MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5448f336969413.73910251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C450F49C-0B25-4580-AD4B-44974C11E79A</gtr:id><gtr:title>Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1e863e501dee503acf8b635e2154529"><gtr:id>f1e863e501dee503acf8b635e2154529</gtr:id><gtr:otherNames>Dicks MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56b88a5d129523.46899657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>550E651F-664C-4E16-9225-77EDF6A8C8BC</gtr:id><gtr:title>Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad78882d25f801f5874af5ec73f5a4"><gtr:id>acad78882d25f801f5874af5ec73f5a4</gtr:id><gtr:otherNames>Kim EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5448f3d5d1b452.75582824</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001081</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>